2[23]Dube M P, Johnson D L, Currier J S, et al. Protease inhibitor-associated hyperglycaemia[J]. Lancet, 1997, 350: 713-714.
3[24]Blanche s, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues[J]. Lancet, 1999, 354: 1084-1089.
4[25]Ciesielski C A, Metler R P, Msph R N. Duration of time betneen exposure and seroconversion in healthcare workers with occupationally acquired infection with human immunodeficiency virus[J]. Am J Med, 1997, 102(5B): 115-116.
5[26]Busch M P, Satten G A. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure[J]. Am J Med, 1997, 102(5B): 117-124.
6[27]Ridzon R, Gallagher K, Ciesielski C, et al. Simultaneous of human immunodeficiency virus and hepatitis C virus from a needle-stick injury[J]. N Engl J Med, 1997, 336(13): 919-922.
7[28]Descanms D, Flandre P, Clavez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy[J]. JAMA, 2000, 283(2): 205-211.
8[29]Devereux H L, Youle M, Johnson M A, et al. Rapid decline in detectability of HIV-I drug resistance mutations after stopping therapy[J]. AIDS, 1999, 13(18): F123-127.
9[1]Spira A I, Marx P A, Patterson B K, et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immuodeficiency virus into rhesus macaques[J]. J Exp Med, 1996, 183: 215-225.
10[2]Pope M, Gezelter S, Gallo N, et al. Low levels of HIV-1 infection in cutaneous dendritic cells promote extensive viral replication upon binding to memory CD+4 T cells[J]. J Exp Med, 1995, 1982: 2045-2056.
